key: cord-0689142-09p0on6e
authors: Kow, Chia Siang; Merchant, Hamid A.; Hasan, Syed Shahzad
title: Mortality risk in patients infected with SARS-CoV-2 of the lineage B.1.1.7 in the UK
date: 2021-05-13
journal: J Infect
DOI: 10.1016/j.jinf.2021.05.008
sha: 5adbb70e282c6700d96299c8d344b902abe8e378
doc_id: 689142
cord_uid: 09p0on6e

nan

syndrome coronavirus 2 (SARS-CoV-2) of the lineage B.1.1.7 in Tenerife, Spain. This should be a cause for concern because based on current observations, among patients with coronavirus disease 2019 (COVID-19), SARS-CoV-2 of the lineage B.1.1.7 persisted longer in the respiratory tract of infected patients and attained higher viral RNA loads compared to those of other variants [2, 3] . Therefore, the findings indicate the possibility for more severe illness and higher rate of mortality apart from higher transmissibility, in patients infected with SARS-CoV-2 of the lineage B.1.1.7, compared to other variants [2, 3] . There had been attempts to investigate if the mortality rate of patients with COVID-19 infected with SARS-CoV-2 of the lineage B.1.1.7 is higher compared to those infected with other variants. Therefore, we aimed to perform a meta-analysis to summarize the overall risk of mortality in patients Two investigators (CSK and SSH) extracted the study characteristics, which included the first author's surname, country of origin, study methods, study population, and mortality estimates. Meta-analyses with the random-effects model were used to estimate the pooled hazard ratio of mortality in patients with COVID-19 infected with SARS-CoV-2 of the lineage B.1.1.7 relative to their counterparts infected with other variants, at 95% confidence intervals. We examined the heterogeneity between studies using the I 2 statistics and the χ2 test, with significant heterogeneity predetermined at 50% and P<0.10, respectively. All analyses were performed using Meta XL, version 5.3 (EpiGear International, Queensland, Australia).

Our systematic literature search retrieved 265 hits, of which 207 were unique (titles retrieved after removing duplications). After screening against eligibility criteria, four observational studies [4] [5] [6] [7] were included, with a total of 2,738,113 patients with COVID-19. All included studies [4] [5] [6] [7] were originated from the United Kingdom. Table 1 summarizes the characteristics of the four included studies [3] [4] [5] [6] which evaluated the risk of mortality between patients with COVID-19 infected with SARS-CoV-2 of the lineage B.1.1.7 and those infected with other variants. The meta-analysis of four studies with mortality estimates as hazard ratio indicates significantly increased hazard of mortality (Figure 1 ; pooled hazard ratio=1.45; 95% confidence interval: 1.18 -1.78). The pooled hazard ratio remained significant even after excluding the critical care cohort of patients from the study by Patone et al. [7] (pooled hazard ratio=1.60; 95% confidence interval: 1.47 -1.74).

The evidence to date pointed towards increased risk of mortality in patients infected with SARS-CoV-2 of the lineage B.1.1.7, compared to other variants, which might be due to the modified viral dynamics as mentioned beforehand [2, 3] . In addition, increased binding affinity between the Spike receptor-binding domain and angiotensin-converting enzyme 2 (ACE2) receptor with SARS-CoV-2 of the lineage B.1.1.7 as previously reported could lead to more ACE2 downregulation should an individual acquire this new variant compared to other variants; ACE2 might have a protective effect against lung injury in patients with COVID-19 [8, 9] . The patients contracting COVID-19 may be screened for the B.1.1.7 variant and should be clinically monitored early in the disease course so that an aggressive therapeutic intervention can be offered in time to reduce risk of mortality [10] .

Funding: This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

All authors report no conflicts of interest relevant to this article. 

Monitoring the rise of the SARS-CoV-2 lineage B.1.1.7 in Tenerife (Spain) since mid

Infection sustained by lineage B.1.1.7 of SARS-CoV-2 is characterised by longer persistence and higher viral RNA loads in nasopharyngeal swabs

Viral dynamics in mild and severe cases of COVID-19

Case fatality risk of the SARS-CoV-2 variant of concern B.1.1.7 in England

Increased mortality in communitytested cases of SARS-CoV-2 lineage B.1.1.7 [published online ahead of print

Risk of mortality in patients infected with SARS-CoV-2 variant of concern 202012/1: matched cohort study

Analysis of severe outcomes associated with the SARS-CoV-2 Variant of Concern 202012/01 in England using ICNARC Case Mix Programme and QResearch databases

SARS-CoV-2 spike protein impairs endothelial function via downregulation of ACE2

ACE2 and COVID-19 and the resulting ARDS

Could it be that the B.1.1.7 lineage is more deadly?